In the largest ever study of smoldering myeloma patients from 13 major myeloma facilities, lenalidomide was found to delay disease progression, and helped prevent bone damage and end organ damage. The study was run by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute.
The study included 182 intermediate or high risk smoldering myeloma patients (between 2013-2017) who were broken into two groups:
- 90 patients received 25 mg of lenalidomide
- 90 patients were observed with no therapy.
The median follow up was 35 months. Progression free survival (PFS) was analyzed from years 1-3 and it was too soon to assess Overall Survival.
|PFS 1 YR||98%||89%|
|PFS 2 YRS||93%||76%|
|PFS 3 YRS||91%||66%|
“Our data, together with the results of the Spanish trial, support early therapy as the new standard of care in high-risk SMM on the basis of clear clinical benefit in the prevention of end-organ damage demonstrated in two independent randomized trials.”
“Early treatment with lenalidomide delays progression to symptomatic myeloma and can prevent damage to organs that occurs in multiple myeloma.”